OppenheimerFunds Inc. grew its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 8.1% during the 4th quarter, HoldingsChannel reports. The fund owned 43,699 shares of the company’s stock after acquiring an additional 3,257 shares during the quarter. OppenheimerFunds Inc.’s holdings in Eli Lilly and were worth $3,690,000 at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Eli Lilly and by 2.3% in the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after buying an additional 1,610,885 shares during the period. BlackRock Inc. increased its stake in shares of Eli Lilly and by 1.2% in the fourth quarter. BlackRock Inc. now owns 63,854,112 shares of the company’s stock worth $5,393,119,000 after buying an additional 776,893 shares during the period. Janus Henderson Group PLC increased its stake in shares of Eli Lilly and by 16.1% in the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock worth $928,719,000 after buying an additional 1,503,918 shares during the period. UBS Asset Management Americas Inc. increased its stake in shares of Eli Lilly and by 1.8% in the fourth quarter. UBS Asset Management Americas Inc. now owns 6,636,386 shares of the company’s stock worth $560,509,000 after buying an additional 115,499 shares during the period. Finally, Dodge & Cox increased its stake in shares of Eli Lilly and by 22,094.9% in the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after buying an additional 5,964,955 shares during the period. 76.79% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Donald A. Zakrowski sold 860 shares of the business’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $76.50, for a total transaction of $65,790.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Jeffrey N. Simmons sold 12,500 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the sale, the senior vice president now owns 124,522 shares in the company, valued at approximately $10,766,172.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 224,761 shares of company stock worth $19,708,235. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Co (LLY) opened at $79.61 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. The stock has a market cap of $86,431.72, a price-to-earnings ratio of -398.03, a price-to-earnings-growth ratio of 1.47 and a beta of 0.28. Eli Lilly and Co has a 1 year low of $73.69 and a 1 year high of $89.09.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. During the same period in the previous year, the firm earned $0.95 EPS. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. equities research analysts predict that Eli Lilly and Co will post 4.87 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, March 9th. Stockholders of record on Thursday, February 15th were issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.83%. The ex-dividend date of this dividend was Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is -1,124.94%.
ILLEGAL ACTIVITY WARNING: “OppenheimerFunds Inc. Boosts Holdings in Eli Lilly and Co (LLY)” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3253219/oppenheimerfunds-inc-boosts-holdings-in-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.